The agreement brings an end to the legal dispute between the two companies. Hims & Hers shares jumped.
Hims & Hers Health has agreed to stop selling compound versions of Novo Nordisk’s Wegovy and other weight-loss drugs, ending ...
Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would ...
March 9 (Reuters) - Hims & Hers' shares were up over 50% in premarket trading on Monday, after Novo Nordisk agreed to sell ...
Shares of Hims & Hers jumped as much as 55% Monday after Novo Nordisk announced it is dropping its lawsuit over Ozempic and ...
Investing.com -- Hims & Hers Health shares climbed as much as 7.2% in premarket trading on Thursday, following a 10% rally on Wednesday. The stock is set to extend its advance for a fourth straight ...
Two healthcare names are drawing fresh analyst attention this week as Wall Street recalibrates around a landmark GLP-1 truce ...
Hims & Hers Health, Inc.'s revenue is projected to reach $2.7B in 2026 & $3.2B in 2027, implying less than 2x forward sales. Read more on HIMS stock here.
Yahoo Finance anchor Josh Lipton tracks Wednesday's top moving stocks and biggest market stories in this Market Minute. Hims ...
Hims & Hers extended its winning streak to a third consecutive day on Wednesday, jumping 10.27 percent to close at $25.88 apiece, as investors resumed buying positions after a series of analyst ...
Both companies’ stocks rose in the wake of the news.
Novo Nordisk will sell Wegovy and Ozempic drugs through the telehealth company Hims & Hers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results